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Abstract
Celiac disease (CD) is an autoimmune enteropathy induced by gluten ingestion in
genetically susceptible individuals. Genetic predisposition plays an important role in
the development of CD, but it is not sufficient by itself for the disease development.
Although gluten proteins are the main environmental factor involved in CD pathogen‐
esis and ingestion of gluten is necessary to manifest the disease, recent studies have
suggested that alteration of the microbiota could be involved and, in particular, the
interplay between gut microbiota and the mucosal immune system. Dysbiosis,  the
alteration of the microbiota, has been associated with a variety of intestinal patholo‐
gies including Crohn disease and CD. Most observational studies in children and adults
with CD have shown alterations in the intestinal microbiota composition compared to
control subjects, which is only partially recovered after treatment with a gluten‐free diet
(GFD). At this time, the only treatment for CD is lifelong adherence to a GFD, which
involves the elimination of grains containing gluten, wheat, rye, and barley. However,
it is difficult for many patients to follow a GFD. Abnormalities in the gut microbiome
in  CD  patients  have  led  to  the  use  of  probiotics  as  a  promising  alternative  as  a
therapeutic or preventative approach.
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1. Introduction
Celiac disease (CD) is an autoimmune enteropathy induced by gluten ingestion in genetically
susceptible individuals [1]. The major genetic risk factor for CD is represented by HLA‐DQ
genes. Ninety percent of affected individuals carry the HLA‐DQ2 haplotype, 5% the DQ8
haplotype, and the remaining 5% carry at least one of the two DQ2 alleles [1, 2]. Genetic
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predisposition plays an important role in the development of CD but it is not sufficient by itself
for the disease development [3]. Approximately, 30% of the general population carry the HLA‐
DQ2/8 CD susceptibility genes, however, only 2–5% of these individuals will develop CD,
suggesting  that  additional  environmental  factors  contribute  to  disease  development  [4].
Although gluten proteins are the main environmental factor involved in CD pathogenesis and
ingestion of gluten is necessary to manifest the disease, recent studies have suggested that
potential factors such as birth delivery, breast‐feeding, infectious agents, and antibiotic intake
could contribute to the development of CD [5–7]. The alteration of the microbiota could also be
involved and, in particular, the interplay between gut microbiota and the mucosal immune
system [8].
The microbiota, the set of microorganisms that colonize the human body, has a fundamental
role for the host. It is important for both physiological and metabolic factors, ranging from the
absorption of nutrients to the regulation and development of the immune system [9].
Dysbiosis, the alteration of the microbiota, has been associated with a variety of pathologies
like Crohn disease and obesity [10, 11]. Most observational studies in children and adults with
CD have shown alterations in the intestinal microbiota composition compared to control
subjects, which is partially recovered after treatment with a gluten‐free diet (GFD) [12–14]. It
has been demonstrated that levels of Bifidobacteria and Lactobacilli are reduced in CD patients
[14, 15]. Specific alterations in the microbiota could contribute to the etiopathogenesis of CD
by providing proteolytic activities that influence the generation of toxic and immunogenic
peptides from gluten, and compromise the intestinal barrier function [16]. Probiotics are
nonpathogenic live microorganisms, which, when orally administered in adequate amounts,
alter the microflora of the host and have beneficial health effect [17].
At this time, the only treatment for CD is lifelong adherence to a GFD, which involves the
elimination of grains containing gluten, wheat, rye, and barley. However, it is difficult for
many patients to follow a GFD. Some probiotics have been found to digest or alter gluten
polypeptides [18]. Abnormalities in the gut microbiome in CD patients have led to the use of
probiotics as a promising alternative as a therapeutic or preventative approach.
Here we focus on the role of microbiota in the pathogenesis of CD and on the chances for
probiotics to be involved in an alternative treatment strategy.
2. Microbiota composition in celiac children
Several research papers have suggested that an important risk factor involved in the etiolo‐
gy of CD could be the gut microbiota. Multiple studies investigating the role of gut microbio‐
ta in CD have been performed on fecal samples and, later, on duodenal biopsies.
The studies that have addressed the relation between fecal microbiota and CD in the pedia‐
tric population are summarized in Table 1 [13, 19–24]. In the earliest report involving a total
of 49 children, 26 celiac patients aged 12–48 months and 23 age‐matched controls, Collado et
al. evaluated the composition of the fecal microbiota by both culture‐dependent and culture‐
Probiotics and Prebiotics in Human Nutrition and Health224
independent methods using fluorescent in situ hybridization (FISH) [13]. They showed a high
level of Bacteroides, Clostridium, and Staphylococcus in fecal samples from CD children com‐
pared to healthy subjects when analyzed by culture methods. The numbers of Bacteroides‐
Prevotella, Clostridium histolyticum, Eubacterium rectale‐Clostridium coccoides, Atopobium, and
sulfate‐reducing bacterial groups were also significantly higher in fecal samples from CD
children analyzed by FISH [13]. Subsequently, Sanz et al. [19], using polymerase chain
reaction (PCR) and denaturing gradient gel electrophoresis (DGGE) in 10 CD children aged
15–45 months and 10 age‐matched healthy controls, demonstrated that the presence of species
such as Lactobacillus curvatus, Leuconostoc mesenteroides, and Leuconostoc carnosus were charac‐
teristic of coeliac patients, while the Lactobacillus casei group was characteristic of healthy
controls. Moreover, the authors found a reduction in Bifidobacterium population diversity in
CD patients. Collado et al. [20], using real‐time PCR, evaluated duodenal and fecal microbio‐
ta in three groups of children: (1) untreated CD patients on a gluten‐containing diet (GCD); (2)
treated CD patients who had been on a GFD for a minimum of two years; and (3) healthy
controls. They found that feces and biopsies of CD patients had an increased presence of
Bifidobacterium, Bacteroides, and Clostridium leptum groups with respect to the control group;
Escherichia coli and Staphylococcus were otherwise predominant in CD subjects on GFD. GFD
determined a complete normalization of gut microbiota [20]. De Palma et al. examined fecal
microbiology and immunoglobulin‐associated features in active and non‐active stages of CD
in children and in age‐matched controls [21]. They found that in CD patients there was an
alteration in the type of fecal immunoglobulin‐coated bacteria along with a shift in the
composition of the microbiota. In fact, they demonstrated a reduction of the percentages of the
IgA‐coated bacteria in CD patients on a GFD and in those not following a GFD compared to
the control group. They also found a reduction of the percentages of IgG‐ and IgM‐coated
bacteria in treated CD patients with respect to untreated CD subjects and control group.
Moreover, treated and untreated CD subjects showed a predominance of Bacteroides‐Prevotella
as well as an impaired mucosal barrier, as suggested by the reduction of IgA‐coated bacteria
with respect to the controls [21]. Sanchez et al., in an attempt to determine whether intestinal
Staphylococcus spp. and their pathogenic features differed between CD patients and healthy
controls, studied 40 CD children (20 active CD and 20 non‐active CD) and 20 healthy con‐
trols [22]. Staphylococci were isolated from feces and identified by PCR and DNA sequencing.
CD was associated with alterations in species diversity and composition of the fecal Staphylo‐
coccus population. Staphylococcus epidermidis isolates carrying the mecA gene and both the mecA
and atIE genes were more abundant in CD patients than in controls, most likely reflecting
increased exposure of these subjects to opportunistic staphylococcal pathogens and antimi‐
crobials, which in turn affected the composition/features of their intestinal microbiota [22]. Di
Cagno et al. in a study including seven CD patients on GFD, seven CD patients on a GCD, and
seven healthy controls, utilizing DGGE analysis and gas chromatography‐mass spectrome‐
try‐solid‐phase microextraction analysis of fecal volatile organic compounds (VOCs), found
that the fecal microbiota and VOCs of CD patients on GFD were more similar to those of healthy
patients than to those of CD patients on GCD [23]. Consequently, the authors speculated that
Lactobacillus and Bifidobacterium strains isolated from healthy children could be a potential
probiotic treatment to restore the balance of intestinal microbiota in treated and untreated CD
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patients [23]. Similar conclusions have been reached by Lorenzo Pisarello et al. [24] in a very
recent work. They found lower counts of Lactobacillus in the feces of CD compared to con‐
trols. Furthermore, the authors selected from feces of controls 5 Lactobacillus strains because of
their high resistance percentages to gastrointestinal tract conditions. Lactobacillus rhamnosus
(LC4) showed the highest percentage of autoaggregation and Lactobacillus paracasei showed
high hydrophobicity suggesting a potential use of these strains as probiotics in CD [24].
Author/
References 
Year Country Patients population
and sample size
Methods Main results
Collado et al.
[13]
2007 Spain 26 untreated CD (mean
age, 26 months)
23 controls (mean age,
23.1 months)
Culture+ FISH In untreated CD:
↑ Bacteroides
↑ Staphylococcus
↑ Clostridium
↑ Bacteroides‐Prevotella,
↑ Clostridium hystoliticum,
↑ Eubacterium rectale‐C. coccoides,
↑ Atopobium, Staphylococcus
↓ Bifidobacterium
Sanz et al. [19] 2007 Spain 10 untreated CD (mean
age, 28 months)
10 controls (mean age, 24
months)
Culture+qPCR
+DGGE
In untreated CD:
High diversity of fecal microbiota
↑ Leuconostoc carnosum,
↑ Leuconostoc mesenteroides,
↑ Lactobacillus curvatus
↓ Lactobacillus casei,
↓ Bifidobacterium adolescentis
Collado et al.
[20]
2009 Spain 30 untreated CD (mean
age, 38.5 months)
18 treated CD (mean age,
37.7 months)
30 controls (mean age,
33.5 months)
qPCR In untreated and treated CD:
↑ Bacterial count
↑ E. coli,
↑ Bacteroides,
↑ Clostridium leptum
Staphylococcus prevalence
↓ Bifidobacterium
In treated CD:
↑ Lactobacillus
Di Cagno et al.
[23]
2009 Italy 7 untreated CD (range, 6–
12 years)
7 treated CD (range, 6–12
years)
7 (range, 6–12 years)
controls
PCR+DGGE In treated and untreated CD:
↓ Ratio of cultivable lactic acid
bacteria and Bifidobacterium to
Bacteroides and Enterobacteria
In treated CD and in controls:
Lactobacillus brevis, Lactobacillus
rossiae, Lactobacillus pentosus
Only in controls:
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Author/
References 
Year Country Patients population
and sample size
Methods Main results
Lactobacillus fermentum, Lactobacillus
delbrueckii subsp., Lactobacillus
bulgaricus, Lactobacillus gasseri
De Palma et al.
[21]
2010 Spain 24 untreated CD (mean
age, 5.5 years)
18 treated CD (mean age,
5.5 years)
20 controls (mean age, 5.3
years)
FISH+ flow
cytometry
In untreated CD:
↓ Bifidobacterium,
↓ Clostridium histoliticum,
↓ Clostridium lituseburense,
↓ Fecalibacterium prausnitzii
↑ Bacteroides‐Prevotella
In untreated CD and in controls:
↓ Levels of IgA coating the
Bacteroides‐Prevotella
Sanchez et al.
[22]
2012 Spain 20 (mean age, 57.4
months) untreated CD
20 (mean age, 67.3
months) treated CD
20 (mean age, 54.0
months) controls
PCR+ DNA
sequencing
In untreated CD:
↑ Staphylococcus spp. diversity
↑ Staphylococcus haemolyticus
↓ Staphylococcus aureus
↑ mecA and atIE genes in S.
epidermidis clones
Lorenzo Pisarello
et al. [24]
2015 Argentina 15 treated CD (mean age,
7.5 years)
15 controls (mean age, 6.5
years)
Culture
(autoaggregation
assay,
hydrophobicity
assay)
In treated CD
↓ Lactobacilli
↑ Enterobacteria
Lactobacillus rhamnosus and
Lactobacillus paracasei identified to
improve sign and
symptom in CD
CD celiac disease, FISH fluorescent in situ hybridization, DGGE denaturing gradient gel electrophoresis, PCR polymerase
chain reaction, qPCR quantitative polymerase chain reaction.
Table 1. Fecal microbiota in celiac disease.
Duodenal microbial composition of pediatric CD patients was explored more extensively later
on, with the main findings summarized in Table 2 [20, 25–33]. Microbiota characterization
from duodenal biopsy specimens was initially carried out on CD Spanish children by Nadal
et al. [25] in 2007. The authors, in an attempt to identify the specific composition of the duodenal
microbiota of celiac patients (with active and non‐active disease), evaluated 20 CD patients on
GCD, 10 CD patients on GFD for 1–2 years, and 8 healthy controls. Bacteriological analyses of
duodenal biopsy specimens, carried out by fluorescent in situ hybridization coupled with flow
cytometry, showed that the proportions of total and Gram‐negative potentially pro‐inflam‐
matory bacteria were significantly higher in CD patients with active disease than in patients
on GFD and controls. Although, the ratio of beneficial bacterial groups (Lactobacillus‐
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Bifidobacterium) to potentially harmful Bacteroides‐E. coli was significantly reduced in CD
patients on GFD, there was not a complete normalization of gut microbiota compared with
controls [25]. Several subsequent Spanish studies confirmed these results [20, 26–28].
Particularly, these studies found that the Bacteroides, E. coli, Bifidobacterium, Enterobacteriacae,
and Staphylococcus groups were significantly more abundant in GCD patients than in the
controls with a greater diversity of these species [20, 26, 28], while, in contrast, members of the
family Streptococcaceae were less abundant in CD patients [28]. Furthermore, the Prevotella
genera were more frequent in healthy subjects than in celiac patients [27]. Ou et al. identi‐
fied Clostridium, Prevotella and Actinomyces as predominant bacteria in the proximal small
intestine biopsies from a cohort of 45 CD children and 18 healthy controls born during the so‐
called “Swedish CD epidemic” (2004‐2007). This could explain the four‐fold increase in the
incidence of CD in children less than two years of age observed between 2004 and 2007 [29].
Schippa et al. [30] analyzed the mucosa‐associated microbiota of CD children, before and after
a GFD, and controls by temporal temperature gradient gel electrophoresis (TTGE). The most
important findings of the study were: a demonstration of a presence of peculiar microbial
TTGE profile and a significant higher biodiversity in CD pediatric patients’ duodenal mucosa
after 9 months of GFD compared to healthy controls. Di Cagno et al. [31], utilizing culture‐
dependent and culture‐independent methods and metabolomics analyses, investigated the
differences in the microbiota and metabolome of 19 treated CD patients and 15 controls. They
confirmed the lower levels of Lactobacillus and increased levels of Bacteroides in CD patients.
Moreover, the authors showed that a GFD lasting at least two years did not completely restore
the microbiota and metabolome in CD patients [31]. A recent Spanish study demonstrated that
the intestinal microbiota of patients with duodenal Marsh 3c lesions showed similarity of 98%
and differed from that of CD patients with other type of histologic lesion as Marsh 3a, Marsh 3b,
and Marsh 2 [32]. This indicated that the composition of duodenal microbiota differed
depending on the grade of intestinal damage.
Authors/
references 
Years Country  Patients population
and sample size
Methods Main results
Nadal et al. [25] 2007 Spain 20 (untreated CD (mean
age, 5.1 years)
10 treated CD (mean age,
5.6 years)
8 controls (mean age, 4.1
years)
FISH+ flow
cytometry
In untreated CD:
↑ Total bacteria
↑ Gram‐negative bacteria
↑ Bacteroides and E. coli, which
normalized after GFD
In treated and untreated CD:
↓ The ratio of Lactobacillus‐
Bifidobacterium to Bacteroides
Collado et al.
[20]
2009 Spain 8 untreated CD (mean age,
56.4 months)
8 treated CD (mean age,
65.2 months)
qPCR In untreated CD:
↑Bacterial counts
↑ Lactobacillus prevalence
↓ C. coccoides prevalence
↑ Staphylococcus
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Authors/
references 
Years Country  Patients population
and sample size
Methods Main results
8 controls (mean age, 45.0
months)
↑ E. coli
↓ Bifidobacterium
In treated and untreated CD:
↑ Bacteroides
↑ C. leptum
Ou et al.[29] 2009 Sweden 33 untreated CD (median
age, 5.9 years)
17 treated CD (median age,
7.5 years)
3 challenged CD (median
age, 10.8 years)
18 controls (mean age, 3.2
years)
Culture
+Scanning
electron
microscopy
In untreated CD
↑ Streptococcus
↑ Neisseria
Schippa et al.
[30]
2010 Italy 20 CD (before and after
GFD) (mean age, 8.3 years)
10 controls (mean age, 11.7
years)
TTGE Differences in biodiversity between
untreated CD and treated CD
↑Bacteroides vulgatus and E. coli in CD
Sanchez et al.
[26]
2010 Spain 20 treated CD (mean age,
51.1 months)
12 untreated CD (mean
age, 54.9 months)
8 controls (mean age, 50.1
months)
PCR‐DDGE In untreated and treated CD:
↓Bacteroides diversity
In untreated CD:
↓ Bacteroides dorei
↑Bifidobacterium diversity
↑Bifidobacterium adolescentis,
↑ Bifidobacterium animalis
↓Bacteroides diastonis, ↓Bacteroides
fragilis
↓ Bacteroides thetaiotaomicron,
↓ Bacteroides uniformis
↓ Bacteroides Ovatus
Di Cagno et al.
[31]
2011 Italy 19 treated CD (mean age
9.7 years)
15 controls (mean age, 10.4
years)
PCR‐DDGE In treated CD:
↓ Lactobacillus
↓ Enterococcus
↓ Bifidobacteria
↑Bacteroides,
↑ Staphylococcus, ↑Salmonella,
↑ Shigella, Klebsiella
Sanchez et al.
[28]
2013 Spain 32 untreated CD ( mean
age, 5.1 years)
17 treated CD (mean age,
5.9 years)
Culture
+PCR
In untreated CD:
↑ Proteobacteria, Enterobacteriaceae,
Staphylococcaceae (Klebsiella oxytoca,
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Authors/
references 
Years Country  Patients population
and sample size
Methods Main results
8 controls (mean age, 6.9
years)
Staphylococcus epidermidis,
Staphylococcus pausteri)
↓ Firmicutes
↓ Streptococcus anginosus,
↓ Streptococcus mutans
Nistal et al. [27] 2012 8 untreated CD (mean age,
3.75 years)
5 controls (mean age, 7.2
years)
16SrRNA
gene
sequencing
↓ Streptococcus and Prevotella
De Meij et al.
[32]
2013 Netherland 21 untreated CD (median
age, 6.8 years)
21 controls (median age,
8.1 years)
IS‐pro In treated and untreated CD:
↑Streptococcus
↑ Lactobacillus
↑ Clostridium
Cheng et al. [33] 2013 Finland 10 untreated CD (median
age 9.5 years)
9 controls (median age, 8.5
years)
qRT‐PCR+
HIPchip
microarray
No significant differences in the
abundance of bacterial phylum‐like
groups between CD and controls
The bacterial diversity was
comparable between CD and controls
In treated and untreated CD:
↑TLR2 expression
↑ IL‐10, IFN‐g, C-X-C chemokine
receptor type 6 expression
Giron
Fernandez‐
Crehuet et al.
[34]
2015 Spain 11untreated CD (median
age, 5.0 years)
6 controls (median age, 8.8
years)
DGGE The intestinal microbiota of children
with Marsh 3c lesion showed
similarity of 98% and differs from
other CD children with lesion as
Marsh 3a, 3b and Marsh 2
In CD: ↓ Richness,
diversity and abitability of Lactobacillus
In untreated CD: ↓ Streptococcus,
Bacteroides, E. coli In controls
↓ Streptococcus, Bacteroides
↑ Bifidobacterium, Lactobacillus,
Acinetobacter
CD celiac disease, FISH fluorescent in situ hybridization, DGGE denaturing gradient gel electrophoresis, GFD gluten‐free
diet, HIPchip Human Intestinal Tract Chip, IFN‐g interferon‐gamma, IL‐10 interleukin‐10, IS‐pro 16S‐23S interspacer, PCR
polymerase chain reaction, qPCR quantitative polymerase chain reaction, qRT‐PCR quantitative reverse‐transcriptase‐
polymerase chain reaction, TGGE temporal temperature gradient gelelectrophoresis, TLR2 toll‐like receptor 2, C-X-C
chemokine receptor type 6.
Table 2. Duodenal‐associated microbiota in celiac disease.
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In contrast, two recent studies reached different results. De Meij et al. [33], analyzing the total
microbiome profile in small bowel biopsies of 21 untreated CD and 21 age‐matched controls,
found that mucosa‐associated duodenal microbiome composition and diversity did not differ
between children with untreated CD and controls. The same results were obtained by Cheng
et al. using bacterial phylogenetic microarray to comprehensively profile the microbiota in
duodenal biopsies of 10 CD and nine healthy children, suggesting that the duodenal mucosa‐
associated bacteria do not play an important role in the pathogenesis of CD [34].
In summary, although the majority of the studies available have confirmed the presence of
intestinal dysbiosis in CD children characterized by low levels of Lactobacilli and Bifidobacte‐
ria and increase in Gram‐negative bacteria (Bacteroides), which were not completely normal‐
ized after GFD, some of them have failed to find a distinct signature that defines celiac
microbiota. The available articles regarding the relationship between the gut microbiota and
GFD, demonstrated that a GFD only allows a partial recovery of the gut microbiota in CD
patients [30, 34, 35].
3. Pathogenetic role of intestinal dysbiosis in CD
The intestinal microbiota composition and function play a fundamental role in the balance
between the host's health and disease by different mechanisms: (1) regulation of epithelial cell
proliferation and expression of tight junction proteins which act on intestinal permeability; (2)
influence on mucin gene expression by goblet cells and their glycosylation pattern; 3) secretion
of antimicrobial peptides (defensins, angiogenins, Reg3γ, etc.) by intestinal cells, which
contribute to control gut bacterial adhesion. Certain components of the gut microbiota also
affect the expression and activation of pattern recognition receptors (PRR), such as toll‐like
receptors (TLRs), which are expressed by epithelial cells and innate immune cells. The
mammalian TLR recognizes specific patterns of microbial components, called pathogen‐
associated molecular patterns (PAMPs). After the PRR‐PAMP interaction, activated innate
immune cells start the adaptive immune response by presenting the antigen and by produc‐
ing cytokines, which leads to antigen‐specific, protective immune response. In inflammatory
and autoimmune diseases this response causes damage to host's tissues [36]. The gut micro‐
biota impacts on adaptive immunity. Recently, specific commensal bacteria have been shown
to influence T lymphocyte production (Th1, Th17) or anti‐inflammatory regulatory T cells
(Tregs) [36].
To date, human microbiota and mucosal barrier function are the key players in etiology of
many inflammatory and autoimmune diseases [37]. Changes in mechanisms regulating
mucosal immunity and tolerance, can lead to impaired mucosal barrier function, increased
penetration of microbial components from lumen into the mucosa and circulation, and
consequently lead exaggeration of aberrant immune responses and inflammation.
The exact mechanisms through which the gut microbiota might influence CD onset or
progression is unknown, but could include activation of innate immune system, modulation
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of the epithelial barrier, or exacerbation of the gliadin‐specific immune response [38].
Moreover, the presence of microbiota can significantly influence the inflammatory effect of
gluten. The microbiota may facilitate the access of gliadin peptides to the lamina propria and
its interaction with infiltrated lymphocytes and antigen presenting cells (APCs) responsible
for triggering the immune response via different mechanisms. In genetically predisposed
individuals, gluten in association with microbial antigens can stimulate and modulate innate
and adaptative immune response, sustaining a chronic mucosal inflammation, underlining
this chronic disease [38].
4. Probiotics in the treatment of CD
Probiotics are nonpathogenic live microorganisms, which when orally administered in
adequate amounts, alter the microflora of the host and have beneficial health effects. Probiotics
have shown to preserve the intestinal barrier promoting its integrity both in vitro and in
vivo [39, 40] as well as regulating the response of the innate and adaptative immune system.
The association of CD with intestinal dysbiosis and the evidence supporting a role for the
microbiota and specific bacteria in maintaining gut barrier function and regulating the
response of the innate and adaptive immune system, have supported the potential use of
probiotics in CD treatment [41, 42]. Although the data regarding the use of probiotics for CD
are encouraging, most of these data come from in vitro experimental models of CD [43, 44].
Studies regarding probiotics and CD in humans are very scarce [45–47]. Smecuol et al.
evaluated the effect of the Bifidobacterium infantis natren life start (NLS) on gut permeability,
the occurrence of symptoms, and presence of inflammatory cytokines in adult CD patients on
GCD. Results have shown that probiotics did not modify intestinal permeability probably due
to an insufficient dose or a short time of administration. However, probiotic administration
improved gastrointestinal symptoms, alleviating and reducing constipation [47].
In children, the clinical trials performed on the effect of probiotics on CD are summarized in
Table 3. In the earliest study Olivares et al. [45] evaluated the influence of Bifidobacterium
longum CECT 7347 in addition to a GFD in children newly diagnosed with CD. They showed
a decrease in peripheral CD3+ T lymphocytes and a trend in the reduction of tumor necrosis
factor (TNF)‐α serum levels, and a reduction in the Bacteroides fragilis group(pro‐inflammato‐
ry bacteria) and in the content of IgA in stools. Klemenak et al. [46] evaluated the effect of a
combination of the strains Bifidobacterium breve BR03 and B. breve B632, as compared to placebo.
They reported that B. breve strains decreased the production of the pro‐inflammatory cyto‐
kine TNF‐α in children CD on a GFD.
At this time, the only treatment for CD is lifelong GFD, which involves the elimination of grains
containing gluten, wheat, rye, and barley in addition to food products and additives derived
from them [48]. To date, adherence to a diet is difficult for many patients. Studies have shown
that dietary transgression in patients with CD is common and can occur anywhere from 32%
to 55% [49]. Moreover, a GFD may be rich in high glycemic index foods which can increase
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insulin resistance and, thus, the risk of obesity and cardiovascular disease. In the last decade,
new therapies have been suggested to improve compliance to a GFD or to replace a GFD [50].
The use of probiotics appears to be able to reduce the damage caused by eating gluten‐
containing foods and may even accelerate mucosal healing after the initiation of GFD [50, 51].
A specific commercially available probiotic, VSL#3 (containing eight different bacteria), has
been shown to reduce the toxicity of gluten when used in a fermentation process [52]. It is
thought that the gut microbiota can be modified in its composition and function by probiotic
administration. These may counteract or postpone the onset of CD, and it can be useful in
patients on GFD, when the normal composition of the intestinal flora has not yet fully
recovered.
Authors/
references 
Years Country  Study
design 
Patients population
and sample size
Main results Comments
Olivares et al.
[45]
2013 Spain DB, R, PC 18 CD (mean age, 6.8 years)
received B. longum CECT
7347; 18 CD (mean age 8.5
years) received placebo for
3 months in parallel with
the GFD
↓B. fragilis group
↓activated T‐
lymphocytes↓
TNF‐α
B. longum CECT 7347
could improve the health
status of CD patients
Klemenac et al.
[46]
2015 Italy
Slovenia
DB, R, PC 22 CD (age, 10.43) daily
received B. breve
25 CD (age, 10.81) daily
received placebo for 3
months
18 (age, 8.83) controls
↓TNF‐α levels on
CD group
Probiotic intervention
with B. breve strains has
shown a positive effect
on decreasing the
production of pro‐
inflammatory cytokine
TNF‐α in children with
CD on GFD
CD celiac disease, DB double-blind, R randomized, PC placebo controlled.
Table 3. Clinical trials on the effect of probiotics for CD.
5. Conclusions
An alternative treatment that can improve CD patients’ quality of life may lie in probiotics. In
particular, probiotics such as Lactobacilli and Bifidobacterium could be useful to reset altered gut
microbiota, as well as reduce gliadin toxicity and immune activation. Their use as a primary
prophylactic treatment for children at high risk of CD is also a potential consideration.
However, their use in routine clinical practice is hindered by limited data from human studies.
The role of specific probiotics and their mechanism of action need to be identified in a larger
experimental population to confirm their effectiveness.
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